We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?
Read MoreHide Full Article
Neurocrine Biosciences, Inc. (NBIX - Free Report) is scheduled to report third-quarter 2020 results on Nov 9, after market close.
In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate by 24.62%. Neurocrine’s track record is decent as it topped estimates in three of the last four quarters, the average earnings surprise being 8.36%.
Neurocrine’s shares have declined 8.2% compared with the industry’s decrease of 11.3%.
Let’s see how things have shaped up for this announcement.
Factors to Note
Neurocrine's Ingrezza, that is approved for treating adults with tardive dyskinesia has been the majority revenue generator for the company since its approval in 2017. The drug has shown strong demand trend in the past couple of years. Despite coronavirus pandemic, the drug’s sales growth was encouraging in the first half of 2020. We expect the uptrend to have continued in the third quarter.
However, we note that initiation of treatment for new patients with Ingrezza was significantly hurt during the second quarter due to COVID-19 related restrictions. Moreover, the company stated on its second-quarter earnings call that the third quarter has been typically a slower quarter for Ingrezza’s sales growth. Thus, the company does not expect significant increase in new patient starts.
Apart from Ingrezza, the company also earns revenues through its collaboration with AbbVie (ABBV - Free Report) and a few other companies. Revenues may vary from one quarter to quarter depending on payment of certain development, regulatory and commercial milestones as well as royalties on sales of AbbVie’s Orilissa.
Meanwhile, Neurocrine launched another drug, Ongentys, in September. The drug received approval in April 2020 from the FDA as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients. Although the drug is unlikely to have brought significant revenues for the company, commercial activities to support its launch may have driven operating expense higher during the third quarter.
Neurocrine is also developing 10 different therapies targeting different neurological, endocrine or psychiatric disorders in clinical studies. Clinical activities are likely to have driven operating expenses further.
We expect the company to provide an update on the outlook for Ingrezza with gradual re-opening of economies amid the pandemic and its progress with its pipeline on the third quarter earnings call.
What Does the Zacks Model Unveil?
Our proven model does not conclusively predict an earnings beat for Neurocrine this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (18 cents per share) and the Zacks Consensus Estimate (11 cents per share), is +64.77%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter
Zacks Rank: Neurocrine currently has a Zacks Rank #5 (Strong Sell).
Here are some stocks you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.
REGENXBIO (RGNX - Free Report) has an Earnings ESP of +4.76% and a Zacks Rank #2.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?
Neurocrine Biosciences, Inc. (NBIX - Free Report) is scheduled to report third-quarter 2020 results on Nov 9, after market close.
In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate by 24.62%. Neurocrine’s track record is decent as it topped estimates in three of the last four quarters, the average earnings surprise being 8.36%.
Neurocrine’s shares have declined 8.2% compared with the industry’s decrease of 11.3%.
Let’s see how things have shaped up for this announcement.
Factors to Note
Neurocrine's Ingrezza, that is approved for treating adults with tardive dyskinesia has been the majority revenue generator for the company since its approval in 2017. The drug has shown strong demand trend in the past couple of years. Despite coronavirus pandemic, the drug’s sales growth was encouraging in the first half of 2020. We expect the uptrend to have continued in the third quarter.
However, we note that initiation of treatment for new patients with Ingrezza was significantly hurt during the second quarter due to COVID-19 related restrictions. Moreover, the company stated on its second-quarter earnings call that the third quarter has been typically a slower quarter for Ingrezza’s sales growth. Thus, the company does not expect significant increase in new patient starts.
Apart from Ingrezza, the company also earns revenues through its collaboration with AbbVie (ABBV - Free Report) and a few other companies. Revenues may vary from one quarter to quarter depending on payment of certain development, regulatory and commercial milestones as well as royalties on sales of AbbVie’s Orilissa.
Meanwhile, Neurocrine launched another drug, Ongentys, in September. The drug received approval in April 2020 from the FDA as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients. Although the drug is unlikely to have brought significant revenues for the company, commercial activities to support its launch may have driven operating expense higher during the third quarter.
Neurocrine is also developing 10 different therapies targeting different neurological, endocrine or psychiatric disorders in clinical studies. Clinical activities are likely to have driven operating expenses further.
We expect the company to provide an update on the outlook for Ingrezza with gradual re-opening of economies amid the pandemic and its progress with its pipeline on the third quarter earnings call.
What Does the Zacks Model Unveil?
Our proven model does not conclusively predict an earnings beat for Neurocrine this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (18 cents per share) and the Zacks Consensus Estimate (11 cents per share), is +64.77%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter
Zacks Rank: Neurocrine currently has a Zacks Rank #5 (Strong Sell).
Neurocrine Biosciences, Inc. Price and Consensus
Neurocrine Biosciences, Inc. price-consensus-chart | Neurocrine Biosciences, Inc. Quote
Stocks That Warrant a Look
Here are some stocks you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Coherus BioSciences (CHRS - Free Report) has an Earnings ESP of +13.04% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
REGENXBIO (RGNX - Free Report) has an Earnings ESP of +4.76% and a Zacks Rank #2.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>